| Literature DB >> 30243313 |
Michel Jadoul1, Marina C Berenguer2, Wahid Doss3, Fabrizio Fabrizi4, Jacques Izopet5, Vivekanand Jha6, Nassim Kamar7, Bertram L Kasiske8, Ching-Lung Lai9, José M Morales10, Priti R Patel11, Stanislas Pol12, Marcelo O Silva13, Ethan M Balk14, Craig E Gordon15, Amy Earley16, Mengyang Di17, Paul Martin18.
Abstract
Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy and in those with a kidney transplant. Since the publication of the original Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2008, major advances in HCV management, particularly with the advent of direct-acting antiviral therapies, have now made the cure of HCV possible in CKD patients. In addition, diagnostic techniques have evolved to enable the noninvasive diagnosis of liver fibrosis. Therefore, the Work Group undertook a comprehensive review and update of the KDIGO HCV in CKD Guideline. This Executive Summary highlights key aspects of the guideline recommendations.Entities:
Keywords: KDIGO; antivirals; chronic kidney disease; cryoglobulinemia; dialysis; direct-acting antivirals; glomerular diseases; guideline; hemodialysis; hepatitis C virus; infection control; kidney transplantation; liver testing; nosocomial transmission; screening; systematic review
Mesh：
Substances：
Year: 2018 PMID： 30243313 DOI： 10.1016/j.kint.2018.06.011
Source DB: PubMed Journal: Kidney Int ISSN： 0085-2538 Impact factor: 10.612